The effect of sodium valproate on acetic acid-induced colitis in rats
- 31.12.2016
- Original Article
- Verfasst von
- Ali Najafi
- Ehsan Motaghi
- Mohammad Javad Hosseini
- Masoumeh Ghasemi-Pirbaluti
- Erschienen in
- Inflammopharmacology | Ausgabe 1/2017
Abstract
Ulcerative colitis is a chronic recurrent disease with incomplete treatment options. The current article evaluated the effect of sodium valproate on acetic acid-induced ulcerative colitis in rats. Rats were randomly distributed into six groups including Sham group, colitis control group, sodium valproate treatment groups (50, 100 and 300 mg/kg, i.p.) and dexamethasone-treatment group. Dexamethasone was used as a reference drug. Colitis was induced by intracolonic instillation of 2 mL of 3% acetic acid solution. The efficacy of sodium valproate was evaluated by macroscopical and histopathological scoring systems, hematocrit measurement as well as biochemical analysis including myeloperoxidase (MPO) and pro-inflammatory cytokines assessment. Sodium valproate, particularly with doses of 100 and 300 mg/kg significantly improved weight loss, and macroscopic damage, reduced ulcer area, colon weight, microscopic colitis index and elevated hematocrit level. Biochemical experiments showed elevated levels of colonic MPO activity, interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) in colitis control group. Treatment with sodium valproate at the doses of 100 and 300 mg/Kg) decreased the MPO activity and colonic concentrations of IL-1β, IL-6 and TNF-α. The results provide evidence that sodium valproate has a protective effect in acetic acid-induced ulcerative colitis which might be due to its anti-inflammatory activities, and it may be useful in patients with ulcerative colitis.
Anzeige
- Titel
- The effect of sodium valproate on acetic acid-induced colitis in rats
- Verfasst von
-
Ali Najafi
Ehsan Motaghi
Mohammad Javad Hosseini
Masoumeh Ghasemi-Pirbaluti
- Publikationsdatum
- 31.12.2016
- Verlag
- Springer International Publishing
- Erschienen in
-
Inflammopharmacology / Ausgabe 1/2017
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608 - DOI
- https://doi.org/10.1007/s10787-016-0304-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.